QLT Announces Positive Preliminary Results From Phase 1b Retreatment Trial of QLT091001 in Subjects With Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65

[at noodls] – VANCOUVER, British Columbia, Feb. 27, 2014 (GLOBE NEWSWIRE) — QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (QLT or the Company) today announced positive preliminary results from its international, … more

View todays social media effects on QLTI

View the latest stocks trending across Twitter. Click to view dashboard

See who QLT is hiring next, click here to view